Physician profile
Daniel S Tung
NPI 1134224942
$753,159.42
in general payments reported to CMS, 2019-2025
63 companies · $124K in 2025
The $124K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132K · 2020: $73K · 2021: $110K · 2022: $97K · 2023: $107K · 2024: $110K · 2025: $124K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $288K · Food and Beverage: $21K · Travel and Lodging: $18K · Honoraria: $8,665 · Consulting Fee: $5,690 · Education: $80.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $287,962.82 |
| Food and Beverage | $20,741.95 |
| Travel and Lodging | $17,800.67 |
| Honoraria | $8,665.00 |
| Consulting Fee | $5,690.00 |
| Education | $80.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $248,692.88 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $185,254.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $176,430.53 | 2019-2024 | Farxiga, Lokelma |
| Corcept Therapeutics | $57,984.29 | 2019-2025 | Korlym |
| Amgen INC. | $24,473.12 | 2019-2025 | Tepezza, Repatha, Evenity |
| Cequr Corporation | $18,867.71 | 2021-2025 | Cequr Simplicity |
| Valeritas, INC. | $10,683.91 | 2019 | |
| Sanofi-Aventis U.S. LLC | $8,565.16 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $6,380.53 | 2019-2025 | Strensiq |
| Zealand Pharma US, INC. | $1,811.61 | 2020-2022 | |
| Mannkind Corporation | $1,249.82 | 2020-2024 | Afrezza |
| Beta Bionics, INC. | $1,023.08 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbott Laboratories | $915.81 | 2020-2025 | Freestyle Libre, Freestyle Libre 3, Proclaim |
| Radius Health, INC. | $820.49 | 2019-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $756.87 | 2021-2025 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $675.97 | 2021-2025 | Isturisa, Signifor Lar |
| Xeris Pharmaceuticals, INC. | $630.05 | 2021-2025 | Recorlev, Gvoke Hypopen, Keveyis |
| Horizon Therapeutics Plc | $619.44 | 2020-2023 | Tepezza |
| Abbvie INC. | $616.21 | 2019-2025 | Synthroid |
| Madrigal Pharmaceuticals | $602.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Esperion Therapeutics, INC. | $520.00 | 2020-2025 | Nexletol, Nexlizet |
| Ascensia Diabetes Care US INC. | $504.36 | 2024-2025 | |
| Amarin Pharma, INC. | $421.86 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $421.19 | 2025 | |
| Dexcom, INC. | $381.34 | 2020-2025 | Dexcom G6 Transmitter |
| Intuity Medical INC | $336.03 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Novartis Pharmaceuticals Corporation | $322.96 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.69 | 2019-2025 | Jardiance |
| Companion Medical, INC. | $237.47 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $225.50 | 2019-2023 | Steglatro, Segluromet |
| Ibsa Pharma INC. | $223.43 | 2019-2024 | Tirosint, Tirosint, Licart |
| Amneal Pharmaceuticals LLC | $187.50 | 2019-2025 | Unithroid |
| Kyowa Kirin, INC. | $177.37 | 2023-2025 | Crysvita |
| Ascendis Pharma Endocrinology INC | $166.92 | 2025 | Yorvipath |
| Tandem Diabetes Care, INC. | $147.40 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Astellas Pharma US INC | $139.71 | 2023-2025 | Veozah |
| Insulet Corporation | $113.23 | 2020-2025 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.11 | 2019-2024 | Cycloset |
| Gilead Sciences, INC. | $103.09 | 2019 | |
| Antares Pharma, INC. | $99.40 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Sequel Med Tech, LLC | $86.96 | 2025 | Twiist |
| Currax Pharmaceuticals LLC | $67.92 | 2023-2025 | Contrave, Nexletol, Nexlizet |
| Pfizer INC. | $64.69 | 2022-2023 | |
| Ultragenyx Pharmaceutical INC. | $63.08 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $62.82 | 2019-2022 | |
| Medtronic, INC. | $61.46 | 2022-2023 | Intellis Adaptivestim, Minimed 780g |
| Nevro Corp. | $55.96 | 2022-2023 | Senza |
| Eisai INC. | $53.50 | 2019 | |
| Grt US Holding, INC. | $52.01 | 2021-2022 | |
| Averitas Pharma INC. | $48.49 | 2024 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $42.99 | 2021 | |
| Verity Pharmaceuticals INC. | $42.95 | 2024-2025 | Tlando |
| Ipsen Biopharmaceuticals, INC | $40.44 | 2021-2022 | |
| Amryt Pharma Holdings Ltd | $39.75 | 2023 | Mycapssa, Juxtapid |
| Eusa Pharma (US) LLC | $37.80 | 2022 | |
| Medtronic USA, INC. | $36.17 | 2020 | |
| Tolmar, INC. | $34.26 | 2025 | Jatenzo |
| Vivus LLC | $27.28 | 2020-2021 | |
| Embecta Corp. | $22.84 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Curium US LLC | $21.65 | 2024 | Detectnet |
| Alvogen INC | $19.86 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.16 | 2020 | |
| Senseonics, Incorporated | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Tung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.